{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_notes_note in Note (approximate match)
Status:
US Previously Marketed
Source:
VIDEX by BRISTOL MYERS SQUIBB
(1991)
Source URL:
First approved in 1991
Source:
VIDEX by BRISTOL MYERS SQUIBB
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Didanosine was developed by Bristol-Myers Squibb in collaboration with the NIH for the treatment of HIV-1 infections. Upon administration the drug is metabolized to the active metabolite which inhibits HIV-1 reverse transcriptase both by competing with deoxyadenosine 5'-triphosphate and by its incorporation into viral DNA. Didanosine was approved by FDA under the name Videx (among the other names).
Status:
Possibly Marketed Outside US
Source:
NADA120299
(1982)
Source URL:
First approved in 1982
Source:
NADA120299
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03014596: Not Applicable Interventional Completed Behavioural, Emotional, and Psychosocial Problems
(2017)
Source URL:
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
Status:
Other
Class:
MIXTURE
